Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology

Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande. In January, the FDA approved the company’s small molecule drug tazemetostat (Tazverik) as a treatment for the rare cancer epithelioid sarcoma. The most advanced drug candidate, developed by another Cambridge-based epigenetics biotech, Constellation Pharmaceuticals (NASDAQ: CNST), is a small molecule in mid-stage testing in myelofibrosis, a rare blood cancer. They are both scientific advisors to Omega, which was founded in 2017 by venture capital firm Flagship Pioneering, the company’s only disclosed financial backer.